肝复乐胶囊联合无水酒精瘤内注射治疗原发性肝癌临床观察

Combination of “Ganfule Capsule”and percutaneous ethanol injection therapy for the treatment of primary liver cancer

目的观察肝复乐胶囊联合瘤内无水酒精注射术(PEIT)治疗原发性肝癌(PLC)的临床疗效。方法将74例原发性肝癌患者随机分为两组;对照组37例给予单纯PEIT术治疗,观察组37例给予PEIT术联合肝复乐胶囊口服治疗。结果观察组总有效率为89.19%,对照组为70.27%;两组临床疗效比较差异有统计学意义(P<0.05)。观察组1年生存率为83.87%,对照组为62.50%;两组生存率比较有显著性差异(P<0.05)。两组2年生存率比较无显著性差异(P>0.05)。结论肝复乐胶囊联合PEIT能提高PLC的临床疗效和延长生存期。

Objective To observe the clinical efficacy of ＂Ganfule Capsule＂ and percutaneous ethanol injection therapy （PEIT） for the treatment of primary liver cancer （PLC）. Methods Seventy-four cases were randomized into two groups： control group in which 37 cases were treated by PEIT, and observation group in which 37 cases were treated by PEIT and ＂Ganfule Capsule＂ orally. Results The total effective rate was 89.19% in the observation group and 70.27% in the control group, with a difference between the two groups （P 〈 0.05）. The 1-year survival rate was 83.87% in the observation group and 62.50% in the control group, with a difference between the two groups （P 〈 0.05 ）. No significant difference was found in 2-year survival rate between the two groups （ P 〉 0.05 ）. Conclusion Combined ＂Ganfule Capsule＂ and PEIT can improve the clinical efficacy and prolong the survival time in patients with PLC.